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ABSTRACT
Acetylsalicylic acid (ASA) is known as a cancer preventing agent, but there is no 
data available regarding the effect of ASA on pituitary cells.
We investigated 66 nonfunctioning (NFPA) and growth hormone (GH)-
producing adenomas and 15 normal pituitary samples. Functional assays (cell 
viability, proliferation, flow cytometry cell cycle analysis, caspase-3 activation 
and DNA degradation) were applied to explore the effect of ASA, YM155 (survivin 
inhibitor), survivin-targeting siRNA and TNF-related apoptosis-inducing ligand 
(TRAIL) in RC-4B/C and GH3 cells. Pituitary adenoma xenografts were generated in 
immunocompromised mice.
We found that survivin was overexpressed and TRAIL was downregulated in 
NFPAs compared to normal pituitary tissue. ASA decreased proliferation but did not 
induce apoptosis in pituitary cells. Additionally, ASA treatment decreased cells in S 
phase and increased cells in G2/M phase of the cell cycle. Inhibition of survivin using 
an inhibitor or siRNA-mediated silencing reversed the ASA-induced growth inhibition 
partially. In addition, we also found survivin-independent effects of ASA on the cell 
cycle that were mediated through inhibition of cyclin A, cyclin dependent kinase 2 
(CDK2) and phospho-CDK2. We also aimed to test the effect of acetylsalicylic acid 
in an animal model using RC-4 B/C cells, but in contrast to GH3 cells, RC-4 B/C cells 
failed to adhere and grow a xenograft.
We concluded that ASA inhibited the growth of pituitary adenoma cells. Survivin 
inhibition is a key mechanism explaining its antineoplastic effects. Our results suggest 
that inhibition of survivin with small molecules or ASA could serve as potential 
therapeutic agents in NFPA.
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INTRODUCTION
Clinically nonfunctioning pituitary adenomas 
(NFPAs) constitute approximately 30-40% of pituitary 
adenomas [1, 2] with the majority being of gonadotrophic 
origin. While recurrent somatic mutations have not been 
identified in NFPAs [3], epigenetic alterations have been 
described both in oncogenes, such as PTTG, POUF1, 
AKT2 and HMGA1/2. Further, tumor suppressor genes, 
such as GADD45G, MEG3, PLAGL1 were found to be 
hypermethylated [4]. Alteration in cell cycle regulators, 
such as overexpression of cyclins (CCNA1, B1, B2) and 
decreased expression of cyclin dependent kinase inhibitors 
(CDKN1A, CDKN2A, CDKN1B) are found in most 
pituitary adenoma types [4]. We previously identified 
microRNA-induced altered G2/M transmission in NFPAs 
due to decreased expression of WEE1 kinase and increased 
level of CDC25A in pituitary adenomas [5, 6].
Beside cell cycle alterations, inhibition of apoptosis 
is also a potential mechanism leading to tumorigenesis in 
pituitary adenomas. This could occur due to overexpression 
of GAL3 and BAG1, or decreased expression of DAPK1, 
genes known to regulate apoptosis. Proteomic studies also 
suggest deranged apoptosis in pituitary adenomas [7].
Survivin, a member of inhibitor of apoptosis protein 
(IAP) family, plays a role in both apoptosis inhibition and 
cell cycle regulation, although the mechanism of its action 
has not been clarified. Survivin, together with AURKB and 
INCENP, forms the chromosomal passenger complex, a key 
regulator of mitosis. Elevated survivin expression is present 
in a variety of cancers [8] and its expression correlates with 
aggressiveness and poor survival [9, 10]. Thus, survivin is 
considered as a potential target in cancer therapies [11]. In 
our previous study we performed gene expression profiling 
of G2/M transition regulators in NFPAs compared to normal 
pituitary (NP), and showed that survivin (BIRC5) and Aurora 
kinase B (AURKB), were the most upregulated genes [6]. 
However, little is known about the role of survivin in 
pituitary tumors. In a recent paper published while our work 
was in final preparations, the authors showed that survivin 
associated with invasiveness of pituitary adenomas [10, 12]. 
As survivin is suppressed by acetylsalicylic acid (ASA), 
an agent used as chemoprevention for colorectal cancer 
[13, 14], we studied the therapeutic potential of ASA in 
pituitary tumours, and assess its potential effects on survivin. 
We hypothesized that ASA might affect various cellular 
processes through survivin, that could lead to reduced 
growth and beneficial overall effects.
RESULTS
Survivin is overexpressed in nonfunctioning and 
GH-producing pituitary adenomas
In our previous study performed on 34 NFPA 
and 10 normal pituitary tissue specimens we found that 
survivin was the most upregulated gene at the mRNA 
level (fold change: 5.1; p=0.0004) in NFPA [6]. Now, 
we extended this study to GH-producing adenomas 
with 12 samples and we found that survivin mRNA was 
overexpressed compared to normal pituitary (fold change: 
4.4; p=0.0060).
Next, we investigated survivin protein expression 
in NFPA and GH-secreting pituitary adenomas. Using 
immunohistochemistry staining, we detected only nuclear 
survivin staining in normal pituitary (n=5), NFPA (n=16) 
and GH-producing (n=9) pituitary adenoma tissues. No 
cytoplasmic staining was observed. Survivin protein was 
overall overexpressed in NFPAs (p=0.025) compared to 
normal pituitary (Figure 1A-1B). Analyzing moderate 
and strong positivity we found that 76.9% (13/16) of 
NFPA samples showed higher survivin protein expression 
compared to normal pituitary specimens (p=0.028).
Interestingly, despite of significantly elevated 
mRNA level in GH-secreting adenomas, survivin protein 
increase did not reach significance compared to normal 
pituitary (p>0.05) (Figure 1A-1B).
Survivin mRNA and protein expression did not 
show significant correlation with Ki67 index in NFPA and 
GH-producing pituitary adenoma tissues.
As survivin inhibits apoptosis induced by TNF-
related apoptosis-inducing ligand (TRAIL) and ASA 
enhances and sensitizes cells to TRAIL-induced apoptosis 
in different cell lines and xenograft models [15, 16], we 
investigated TRAIL expression in pituitary adenoma. 
TRAIL was downregulated in nonfunctioning pituitary 
adenoma compared to normal pituitary (Figure 1C).
ASA reduces cell growth mainly by inhibiting 
proliferation and cell cycle and not by apoptosis 
induction in pituitary adenoma cells
Next, we investigated the influence of acetylsalicylic 
acid on pituitary adenoma cell viability, proliferation and 
cell cycle progression. ASA significantly decreased cell 
viability in a dose-dependent manner in the gonadotropin-
secreting RC-4 B/C cell line but not in the growth 
hormone-secreting GH3 cells (Figure 2A). Additionally, 
cell proliferation was also decreased to 64±10.8% by 2.5 
mM (p<0.0001) and to 44±3.9% by 5 mM (p<0.0001) 
ASA treatment in RC-4 B/C cells. In GH3 cells, we could 
not demonstrate a similar inhibitory effect (Figure 2A).
Next, we investigated whether this inhibitory effect 
could be linked to changes in cell cycle. Using flow 
cytometry cell cycle analysis, we observed a decreased 
number of cells residing in S phase (20.5% of untreated 
cells versus 10.8% for 2.5 mM (p=0.004) and 6.5% for 5 
mM (p<0.0001) ASA treatment). The percentage of cells 
accumulating in G2/M phase was also increased upon 
ASA treatment (0.2% of untreated cell versus 1.4% for 
2.5 mM (p=0.92) and 7.8% for 5 mM (p=0.0005) ASA) 
(Figure 2B).
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Published data indicate that beside growth inhibition 
ASA can also induce apoptosis in several tumor cell types. 
However, using Trypan blue staining we could not detect 
an increase in the number of dead cells following ASA 
treatment (Figure 2A). In accordance with these data, we 
also could not demonstrate enhanced DNA degradation 
or increased Caspase-3 activation after 2.5 mM or 5 mM 
ASA treatment (Supplementary Figure 1A-1B). Because 
ASA can specifically sensitize tumor cells to apoptosis 
we evaluated if ASA might be able to augment TRAIL-
mediated apoptosis. However, we found that in pituitary 
cell lines TRAIL was not able to induce apoptosis and 
ASA could not sensitize for TRAIL treatment compared 
to the positive control (Supplementary Figure 1C).
Survivin downregulation is not the exclusive 
mechanism mediating the effect of ASA on 
pituitary adenoma cells
We hypothesized that the ASA-related effect on cell 
proliferation in pituitary adenoma cells might be linked to 
survivin. We found that 1 mM and 5 mM treatment with 
ASA gradually decreased survivin mRNA and protein 
expression in RC-4 B/C cells (Figure 2C).
In order to demonstrate that ASA specifically acts 
through survivin we inhibited survivin using a specific 
small molecule inhibitor, YM155 as well as silencing with 
a specific siRNA. We found that both YM155 and survivin 
siRNA led to dramatic survivin protein decrease in RC-4 
B/C cells (Figure 3A-3B). Using the pharmacologically 
relevant concentrations (0.1-5 μM) of YM155 we detected 
significant reduction of proliferation of RC-4 B/C cells 
(Figure 3C) but not in GH3 cells (Supplementary Figure 
1D). It is noticeable that in higher concentrations (25, 50 
and 100 μM) GH3 cell proliferation was also decreased 
(data not shown). Similarly, survivin-specific siRNA 
treatment did not significantly decrease cell viability 
(Figure 3D). Regarding the cell cycle, unlike ASA, 
treatment with YM155 survivin inhibitor resulted in 
increased accumulation of cells in G2/M phase but not 
a decrease in S phase (Figure 3C-3D). Together, siRNA 
Figure 1: Representative images for survivin immunostaining on pituitary adenomas. (A) Survivin staining localizes in 
cell nuclei. Up: normal pituitary, middle: NFPA, bottom: GH-secreting adenoma. (B) Survivin staining score showing increased survivin 
protein abundance in NFPA tissues compared to normal tissues. (C) TRAIL mRNA expression in pituitary adenomas (NP n=10; NFPA 
n=29; GH n=12) (**: p<0.01).
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knockdown of survivin caused decreased cell growth and 
increased number of cells in G2/M (Figure 3D).
As both ASA and survivin inhibition (siRNA and 
YM155) increased the number of cells accumulating in 
G2/M phase but only ASA decreased the percentage 
of cells in S phase, we investigated how the treatments 
affected G1/S checkpoint regulators (CCNA2, CDK2 
and p-CDK2). We demonstrated that CCNA2, CDK2 
and p-CDK2 were all decreased after ASA treatment 
(Figure 3E) while YM155 treatment or survivin siRNA 
transfection did not alter these (Figure 3F).
Next, to further investigate survivin’s function, we 
transfected RC-4 B/C cells with a survivin-expressing 
vector and assessed cell proliferation. However, survivin 
overexpression did not have any effect on cell proliferation 
measured by Alamar Blue proliferation assay (Figure 3G).
Generation of a gonadotroph pituitary adenoma 
xenograft model in mice
Based on our in vitro results we decided to generate 
a pituitary adenoma animal model using RC-4 B/C cell 
line to test the effect of per os ASA on tumor formation 
and tumor growth. RC-4 B/C xenograft has been never 
generated before, therefore we tried several different 
conditions. We injected severe combined immunodeficient 
(SCID) mice with gradually increasing cell number (5-
20x106 cells/injection). In a preliminary experiment 
tumor cells were injected in 0.2 ml of growth medium, but 
tumor formation did not occur in three weeks. Next, we 
mixed cells with Matrigel before injection, and found that 
injected cells were palpable after 20x106 cells injection 
only in the first two weeks. However, they were not able 
to adhere and grow and they absorbed progressively in 
the following weeks (Supplementary Figure 2). We used 
GH3 cells as a positive xenograft control as it has been 
described in literature. As in vitro ASA did not have an 
effect on GH3 cells we disregarded per os ASA treatment 
in vivo.
DISCUSSION
Our data suggest that ASA decreases cell viability 
and proliferation of pituitary adenoma cells, as reduced 
number of cells are in S phase with cells stalling at the 
G2/M checkpoint. We investigated the mechanism 
Figure 2: Effect of ASA treatment on pituitary adenoma cells. (A) Cell proliferation in RC-4 B/C cells but not GH3 cells 
decreased after 2.5 and 5 mM ASA treatment (B) Cell cycle analysis using flow cytometry in RC-4 B/C cells showed decrease in S phase 
and increase in G2/M phase population upon ASA treatment. (C) Survivin mRNA and protein expression decreased after ASA treatment. 
*: p=0.013; ****: p<0.0001.
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behind this phenomenon hypothesizing that ASA inhibits 
survivin, a molecule overexpressed in NFPAs. ASA 
treatment resulted in proliferative and viability changes 
that resembled the effects of pharmacological (small 
molecule survivin inhibitor) or genetic (survivin-targeting 
siRNA) inhibition of survivin. However, analyzing cell 
cycle phases we observed slight differences. While both 
ASA and survivin inhibition led to an increase in cells in 
Figure 3: Effect of survivin inhibition. (A) Survivin silencing by siRNA on RC-4 B/C cells. (B) Survivin inhibition by YM155, 
a small molecule inhibitor in RC-4 B/C cells. The effect of YM155 (C) and survivin siRNA (D) on pituitary adenoma cell viability, 
proliferation and cell cycle phases of RC-4 B/C cells (see details in the text). (E) Decrease of CCNA2, CDK2 mRNA and CCNA2, total 
CDK2 and p-CDK2 protein abundance following ASA treatment in RC-4 B/C cells. Left: mRNA, middle and right: western blot and 
densitometry. (F) YM155 and survivin siRNA transfection did not significantly alter CCNA2 and CDK2 expression in RC-4 B/C cells. (G) 
Survivin overexpression did not reduce the viability of RC-4 B/C cells. *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.
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Table 1: Sample characteristics
Experiment Clinical diagnosis Sex Age
Immunhistochemistry 
for anterior lobe 
hormones






IHC Nonfunctioning M 38 FSH, LH NA 3.5
IHC Nonfunctioning M 51 FSH NA 2.5
IHC Nonfunctioning F 83 FSH NA <2
IHC Nonfunctioning M 47 FSH, LH NA 2.5
IHC Nonfunctioning F 58 Negative NA 2.5
IHC Nonfunctioning M 72 Negative NA 2.5
IHC Nonfunctioning M 73 FSH, LH 12635 2.5
IHC Nonfunctioning M 44 FSH, LH 4284 3.5
IHC Nonfunctioning F 53 FSH NA 5
IHC Nonfunctioning F 73 FSH, LH 12558 3.5
IHC Nonfunctioning M 44 FSH 4554 2
IHC Nonfunctioning M 76 FSH, LH NA <3
IHC Nonfunctioning M 77 LH, TSH, PRL NA 3
IHC Nonfunctioning M 62 FSH, LH NA 5
IHC Nonfunctioning M 48 FSH, LH NA <3
IHC Nonfunctioning M 52 FSH, LH NA 3
IHC GH-producing F 60 GH, PRL NA <3
IHC GH-producing M 22 GH, PRL 11571 3
IHC GH-producing M 35 GH, PRL NA 6
IHC GH-producing M 49 GH NA <1
IHC GH-producing F 22 GH, PRL NA 4.5
IHC GH-producing F 37 GH NA 3
IHC GH-producing F 48 GH, PRL 3366 10
IHC GH-producing F 43 GH NA 2
IHC GH-producing M 35 GH, PRL NA 4
RT-qPCR Nonfunctioning F 46 Negative 31350 0
RT-qPCR Nonfunctioning F 65 Negative 127.4 2.5
RT-qPCR Nonfunctioning F 70 Negative 15000 0
RT-qPCR Nonfunctioning F 71 NA 12000 0
RT-qPCR Nonfunctioning M 55 Negative 4821 0.6
RT-qPCR Nonfunctioning M 36 ACTH 1750 0
RT-qPCR Nonfunctioning F 29 FSH 6000 0
RT-qPCR Nonfunctioning F 55 Negative 11592 2
RT-qPCR Nonfunctioning M 58 PRL 5130 0
RT-qPCR Nonfunctioning F 75 FSH 8400 0
RT-qPCR Nonfunctioning M 34 FSH 26250 0
RT-qPCR Nonfunctioning M 69 NA 11700 NA
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G2/M, only ASA caused a decrease in the number of cells 
in S phase. Cyclin A2-CDK2 complex has an important 
role during S phase progression [17]. ASA treatment 
resulted in significant cyclin A2 and total/phospho-CDK2 
decrease, but these effects were not seen after YM155 
treatment and survivin siRNA transfection. In line with 
this a previous publication claimed, that survivin inhibition 
leads to G2/M arrest in prostate cancer cells [18]. Based 
on these results we may conclude that ASA can act both 
through and independently from survivin on pituitary cell 
growth.
The effect of ASA on apoptosis is cell type specific 
[19, 20], as some cells (e.g. HT-29 colon adenocarcinoma 
cells) do not show this phenomenon [21]. There are 
Experiment Clinical diagnosis Sex Age
Immunhistochemistry 
for anterior lobe 
hormones






RT-qPCR Nonfunctioning M 74 Negative 26400 3
RT-qPCR Nonfunctioning F 55 Negative NA 2
RT-qPCR Nonfunctioning M 73 Negative NA 1.5
RT-qPCR Nonfunctioning F 40 Negative 19344 2
RT-qPCR Nonfunctioning F 31 Negative NA 4
RT-qPCR Nonfunctioning M 80 Negative NA 1
RT-qPCR Nonfunctioning F 43 Negative NA 0
RT-qPCR Nonfunctioning M 50 Negative NA 2
RT-qPCR Nonfunctioning M 61 Negative 12690 3
RT-qPCR Nonfunctioning M 53 Negative NA 3
RT-qPCR Nonfunctioning F 68 Negative NA 2
RT-qPCR Nonfunctioning M 72 Negative 4420 1
RT-qPCR Nonfunctioning M 55 FSH, LH, TSH 21952 <2
RT-qPCR Nonfunctioning F 48 Negative NA <2
RT-qPCR Nonfunctioning F 60 Negative NA 1
RT-qPCR Nonfunctioning F 50 FSH 1200 0
RT-qPCR Nonfunctioning M 77 NA 7200 NA
RT-qPCR GH-producing F 59 GH 11616 2
RT-qPCR GH-producing F 56 Negative 4800 0
RT-qPCR GH-producing M 56 GH 1960 3
RT-qPCR GH-producing M 51 GH NA 1.5
RT-qPCR GH-producing M 38 GH NA 3
RT-qPCR GH-producing F 61 Negative 6624 1
RT-qPCR GH-producing F 69 GH, FSH, LH, TSH NA <1
RT-qPCR GH-producing M 37 PRL, GH 2160 NA
RT-qPCR GH-producing F 52 PRL, GH, FSH, LH, TSH 960 4
RT-qPCR GH-producing M 20 PRL, GH 14000 4.5
RT-qPCR GH-producing M 55 PRL, GH 90 0
RT-qPCR GH-produNPcing F 53 Negative 5355 0
Abbreviations: F: female, FSH: follicle-stimulating hormone, GH: growth hormone, LH: luteinizing hormone, M: male, NA: 
not available, NFPA: nonfunctioning pituitary adenoma, PRL: prolactin, RT-qPCR: quantitative reverse transcription PCR.
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several suggested mechanisms for the apoptotic effect 
of ASA [20], such as induction of caspase activation, 
inhibition of NF-Κβ and p38 MAP kinase activation [16], 
BCL2 downregulation, induction of BAX translocation 
into the mitochondria [20] and TRAIL downregulation [6]. 
We found that TRAIL was reduced in NFPA tissues. Taken 
the facts that survivin inhibits TRAIL-induced apoptosis 
[22] and ASA can sensitize cells to apoptosis induction 
[15] and can downregulate survivin, the expression 
pattern of these two genes in pituitary adenoma tissues 
raised the possibility that ASA may exert an apoptosis-
inducing effect on pituitary adenoma cells. Interestingly, 
we could not confirm an apoptosis-inducing effect of 
ASA in pituitary cell lines using three different apoptosis 
detection methods. Other publications have also revealed 
that in contrast to other nonsteroidal anti-inflammatory 
drugs, the apoptosis-inducing effect of ASA is not present 
in every cell type [20].
Survivin was found to be overexpressed in most 
human cancers independently of mitotic index [23]. 
Interestingly, survivin expression was demonstrated 
not only in malignant tumors, but in low-grade, benign 
tumors of the central nervous system [24]. In pituitary 
adenoma, we could not show correlation between Ki67 
index and survivin expression. Overexpression of survivin 
by vector construction in pituitary adenoma cells did not 
increase further proliferation indicating that survivin on-
off expression state is probably more important than the 
extent of overexpression. This is supported by a recent 
publications where the authors suggested that survivin 
overexpression was potentially associated with pituitary 
adenoma invasiveness [10].
Regarding cellular localization, cytosolic survivin 
was suggested to function as apoptotic suppressor while 
nuclear survivin is related to cell division regulation 
[23]. In line with these data we detected nuclear survivin 
staining in NFPA and found survivin acting on cell 
proliferation but not on apoptosis in functional in vitro 
experiments. Our results are similar to those published by 
Wasko et al., 2009 and Jankowska et al., 2008 who also 
found nuclear staining in pituitary adenomas [24, 25]. To 
investigate the function of survivin in pituitary adenoma 
cells we chose to use the small molecular weight inhibitor, 
YM155, because similar to acetylsalicylic acid, it has an 
effect on survivin transcription. Survivin transactivation 
requires the binding of a transcription factor complex 
to the promoter. YM155 inhibits Sp-1 and ASA inhibits 
E2F-1 binding to the survivin promoter, hence both agents 
inhibit the formation of the transactivator complex. YM155 
induces apoptosis in p53-deficient cancer cells, and it was 
shown to be effective in in vivo models of different cancers 
[11, 23]. Furthermore, this molecule is under clinical trials 
for the treatment of different cancers [26, 27]. Inhibiting 
survivin by either YM155 or siRNA-mediated silencing 
mimicked the effect of ASA, indicating that survivin is a 
promising target in the treatment of NFPAs.
We attempted to generate a gonadotroph pituitary 
adenoma xenograft using the rat RC-4 B/C cell line, 
which is the only commercially available gonadotropin-
secreting cell line available, in order to test the effect of 
per os ASA on xenograft growth. Such a model has never 
been published before. Despite adjusting experimental 
conditions, the RC-4 B/C xenografts failed to adhere and 
grow, in contrast to GH3 xenografts, precluding us from 
performing in vivo studies to confirm the effects of ASA.
It is important to find novel therapeutic targets 
in NFPAs, where surgery and radiotherapy are the 
only therapeutic options. Due to the lack of specific 
hormone excess causing prominent signs and symptoms, 
these benign tumors are usually discovered when they 
have already caused optical nerve compression, other 
mass effect-associated symptoms, or invaded into the 
surrounding sinuses. At this point, the success of surgical 
removal is not always guaranteed. In the case of NFPAs, 
both ASA and survivin inhibitors could be promising 
options. ASA has the advantage of being widely used for 
thrombosis prevention, as analgesic and anti-inflammatory 
agent.
The only concern with ASA as a potential therapeutic 
agent in pituitary adenomas is the risk of pituitary 
apoplexy. There are reports suggesting anticoagulant 
therapy as relative contraindication in patients with 
known macroadenoma [28]. However, patients with 
macroadenoma who had pituitary apoplexy received 
aggressive anticoagulative and antiplatelet therapy (ASA 
combined with clopidogrel and full-dose enoxaparin), 
therefore, it is unclear if ASA administration as a single 
therapy would increase the risk of apoplexy [28, 29]. 
Semple et al. concluded that the most common triggers 
for pituitary apoplexy are pituitary stimulation, surgery, 
particularly coronary artery surgery and coagulopathy 
[30]. This observation was further confirmed by Vargas 
et al., who could not confirm the role of antiplatelet 
therapy in pituitary apoplexy by bivariate and multivariate 
analysis [31]. Taken together, it is possible that ASA will 
not elevate the risk of pituitary apoplexy, however this 
requires further investigation.
ASA is an effective, well-tolerated, cheap option 
especially compared to other chemotherapeutic drugs. 
Naturally, the antineoplastic and/or preventive effect of 
ASA on NFPAs requires further studies, yet it still seems 
a promising and relatively harmless option.
In summary, our results show that survivin is 
overexpressed in NFPAs but not in GH-secreting 
adenomas. ASA reduces cell viability and proliferation 
in RC-4 B/C cells. Its effect on cell cycle is based partly 
on downregulation of survivin and partly on survivin-
independent inhibition of cyclin A and CDK2. ASA had no 
effect on pituitary cell apoptosis. Our results suggest that 
survivin inhibitors and ASA could be potential therapeutic 




A total of 66 patients diagnosed with pituitary 
adenoma, comprising 45 nonfunctioning and 21 GH-
secreting adenomas, were selected for this study (Table 
1). Pituitary adenoma tissues were surgically removed at 
the National Institute of Clinical Neurosciences, Budapest, 
Hungary between 2007 and 2017. Histological diagnoses 
were performed at the 1st Department of Pathology and 
Experimental Cancer Research, Semmelweis University, 
Budapest, Hungary according to the WHO classification 
[32]. The clinical diagnosis of adenomas was based on 
the hormone levels measured in serum of the patients, 
and on the histological diagnosis including hormone 
expressions. Ten normal pituitary samples for mRNA 
expression analysis were obtained by autopsy within 6 h 
of death from patients with no evidence of any endocrine 
disease (University Clinical Centre, Belgrade, Serbia). For 
immunostaining five normal pituitary samples adjacent 
to pituitary adenomas were used from formalin-fixed 
paraffin-embedded (FFPE) tissue blocks.
The study was approved by the Scientific and 
Research Committee of the Medical Research Council of 
Hungary (0618/15), and the samples were obtained after 
acquiring written informed consent from all patients.
Survivin immunohistochemistry on pituitary 
adenoma
FFPE tissue sections of 16 NFPAs, 9 GH-producing 
pituitary adenomas, 5 normal adenohypophysis and 
a lymph node as positive control were selected for 
immunohistochemical analysis. 4μm-thick sections 
were immunostained following standard procedure as 
we previously described [6]. Anti-survivin antibody 
(71G4B7, #2808, Cell Signaling Technology, ZA, Leiden, 
The Netherlands) was used at 1:4000 dilution. Goat anti-
rabbit immunoglobulin (#P0448, Agilent, Santa Clara, CA, 
USA, 1:200) was applied as secondary antibody. Slides 
were developed with DAB (Novocastra Laboratories) and 
counterstained with haematoxylin. The stained slides were 
digitally scanned with a high-resolution scanner (Pannoramic 
Scan, 3DHISTECH Ltd.), and used for virtual microscopic 
evaluation and quantification with NuclearQuant module of 
the CaseViewer v2.1 software (3DHISTECH Ltd.). Survivin 
staining was scored negative or weak, medium or strong 
positive (see Supplementary Figure 3), and the percentage of 
nuclei with each staining intensity per case were calculated 
by the software. Medium and strong staining was used for 
analysis in comparison of adenoma and normal tissues.
Cell culture and drug treatment
RC-4 B/C (CRL-1903) and GH3 (CCL-82.1) 
cells were purchased from American Type Culture 
Collection (ATCC). Cells were cultured following ATCC 
recommendations and were used for experiments for 
not more than 20 passages. Acetylsalicylic acid (aspirin, 
ASA) was purchased from Sigma Chemical Co. (#A5376, 
St. Louis, MO, USA), and YM155 was obtained from 
Selleckchem (#S1130, Munich, Germany). Stock 
solutions of both compounds were prepared in dimethyl 
sulfoxide (DMSO). Human Recombinant TRAIL was 
purchased from Thermo Fisher Scientific (Waltham, MA, 
USA) and dissolved in nuclease-free water containing 
0.1% BSA according to the manufacturer’s instructions. 
For cell treatment TRAIL was used in 2 ug/ml final 
concentration.
Protein extraction and western blotting
Protein was extracted as we previously published 
[6], and the concentration was determined by BCA assay 
(Sigma, St. Louis, MO, USA). Total protein was separated 
by 10-15% SDS polyacrylamide gel electrophoresis, 
transferred to a PVDF membrane and incubated overnight 
with primary antibodies (survivin (1:500; #2808), CDK2 
(1:1000; #2546), p-CDK2 (1:1000; #2561) from Cell 
Signaling and Cyclin A2 (1:1000; #MA1-154) from 
Thermo Fisher Scientific). For loading control membranes 
were stripped and re-probed using mouse anti-β-actin 
(1:2000, Cell Signalling Technology, ZA, Leiden, The 
Netherlands). Anti-mouse and anti-rabbit HRP-conjugated 
IgGs were used as secondary antibodies (1:2000, 
#P044701, #P044801 Agilent, Santa Clara, CA, USA). 
Band intensities were quantified using Image J software 
(Bethesda, MD, USA).
Viability and proliferation assay
Cell viability and proliferation was assessed by 
Alamar Blue assay (#DAL1025, Thermo Fisher Scientific, 
Waltham, MA, USA). AlamarBlue indicates cell growth 
by detecting metabolic activity of cells therefore it gives 
information about the sum of cell growth/cell number 
and cell viability. Cells were seeded in a 96-well plate 24 
hours before treatment. After the indicated treatment 10% 
Alamar Blue was added to cells and incubated at 37°C 
for 1h. Fluorescence measurement (ex: 560 nm; em: 590 
nm) was performed using a Thermo Scientific Varioskan 
Flash plate reader (Thermo Fisher Scientific, Waltham, 
MA, USA). Cell growth was assessed by counting of live 
and dead cell number in order to verify that the alterations 
were not due to cell viability changes.
Cell cycle analysis
After treatment cells were washed with PBS, 
trypsinized, and pelleted. The supernatant was removed 
and the cells were fixed overnight in 70% ethanol at -20°C. 
Before measurement fixed cells were centrifuged for 5 min 
at 1600 rpm and the pellet was resuspended in extraction 
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buffer (200 mM Na2HPO4, pH=7.8) supplemented with 
10 ug/ml RNase A. After 15 min incubation at room 
temperature propidium iodide solution was added to the mix 
(10 ng/ml final concentration) and incubated for another 
15 min at room temperature. At least 10000 events were 
measured from each sample using a FACSCalibur flow 
cytometer (BD Biosciences, San Jose, CA, USA). The cell 
cycle distribution of cells and the level of apoptosis were 
determined using ModFit and Cell Quest Pro software.
Survivin plasmid and siRNA
To generate survivin-overexpressing cells, they were 
transfected with pcDNA3.1-Birc5 using X-tremeGENE 
HP DNA Transfection Reagent (Sigma, St. Louis, 
MO, USA). The expression level was determined by 
immunoblot analysis at 48 hours after transfection. 
Transfection efficiency was 80%, as evaluated by 
transfection of a GFP-containing plasmid. For survivin 
silencing, cells were transfected with 2 different Locked 
Nucleic Acid small interfering RNAs (siRNAs) against 
survivin (Silencer Select s133761, s133762, Thermo 
Fisher Scientific, Waltham, MA, USA) or a negative 
control siRNA using Lipofectamine RNAiMAX (Thermo 
Fisher Scientific, Waltham, MA, USA). All siRNAs were 
used in 10 nM final concentration. Gene knockdown was 
verified by immunoblot analysis.
Gene expression profiling by TaqMan Low 
Density Array (TLDA)
Expression changes of apoptosis genes were 
measured in 29 nonfunctioning and 12 GH-producing 
pituitary adenomas versus 10 normal pituitary tissues 
with TaqMan Low Density Array (TLDA) (Thermo 
Fisher Scientific, Waltham, MA, USA). Tissue samples 
were stabilized in RNAlater (#AM7020, Thermo 
Fisher Scientific, Waltham, MA, USA) and stored at 
-70°C until total RNA was isolated using miRNeasy 
Mini Kit (#217004, Qiagen, Hilden, Germany). After 
reverse transcription of 1 ug RNA of each samples with 
Superscript III First Strand Synthesis Kit (Thermo Fisher 
Scientific, Waltham, MA, USA), 5 ul product was mixed 
with 55 ul TaqMan Universal PCR Master Mix (Thermo 
Fisher Scientific, Waltham, MA, USA) and 50ul nuclease-
free water. 100 ul mix was loaded into each channel of 
the TLDA cards. RT-qPCR reaction was performed 
using 7900 Fast Real-Time PCR System (Thermo Fisher 
Scientific, Waltham, MA, USA). (Supplementary Table 1).
Individual gene expression measurements using 
RT-qPCR
Total RNA was isolated from cells using RNeasy 
Mini Kit (#74104, Qiagen, Hilden, Germany). RNA 
concentration was measured by NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA). RNA samples were reverse transcribed using 
High-Capacity cDNA Reverse Transcription Kit (Thermo 
Fisher Scientific, Waltham, MA, USA) according to the 
manufacturer’s instructions.
Survivin gene expression was measured using 
predesigned TaqMan gene expression assay (rno-BIRC5: 
Rn00574012_m1, hsa-BIRC5: Hs04194392_s1, hsa-
ACTB: Hs99999903_m1, 18S: Hs99999901_s1) and 
TaqMan Universal Master Mix (Thermo Fisher Scientific, 
Waltham, MA, USA).
CCNA2 and CDK2 gene expression were 
measured using PowerUp SYBR Green Master Mix 
(#A25742, Thermo Fisher Scientific, Waltham, MA, 
USA) and custom designed primers (rno-CCNA2 
forward: GGATGGTAGTTTTGAATCACCCC, 
reverse: GGATGGCCCGCATACTGTTA, rno-CDK2 
forward: GCTTATCAACGCAGAGGGGT and reverse: 
GGGTCACCATTTCGGCAAAG, rno-ACTB forward: 
AGATCAAGATCATTGCTCCTCCT and reverse: 
ACGCAGCTCAGTAACAGTCC).
All measurements were performed in triplicates on 
384-well plates using a Quant Studio 7 Flex Real-Time 
PCR Systems (Thermo Fisher Scientific, Waltham, MA, 
USA). The expression level was calculated by the ddCt 
method.
Construction of Birc5 expressing plasmid
The sequence of rat Birc5 gene was confirmed 
by bidirectional Sanger sequencing. Genomic DNA 
was isolated from RC-4 B/C rat pituitary adenoma 
cells using QIAamp DNA Mini Kit (#51304, Qiagen, 
Hilden, Germany), and the coding sequence was PCR-
amplified using the following custom-made primers 
obtained from Integrated DNA Technologies. Sequences 
5’-3’: BIRC5-ex1F: CGGAAGGCGACTTTTTCCAG; 
BIRC5-ex1R: TGTGTATGAACGCCGAGGTG; BIRC5 
-ex2F: CTCTCGGCCCGGAAAGATT; BIRC5-ex2R: 
TCCAGTTCTTCCCAAAAGACTCC; BIRC5-ex3F: 
AAAGACAGCCGTGGAGATGG; BIRC5-ex3R: TCCC 
TGAGACAGATCCCCAG; BIRC5-ex4F: CTCCC 
TTGGTAGGCGAGC; BIRC5-ex4R: CGGTCTCC 
TGTAAGACACCAA.
Rat cDNA library was prepared from the 
mRNA of RC-4 B/C rat pituitary adenoma cells 
using High-Capacity cDNA Reverse Transcription 
Kit (#4368813, Thermo Fisher Scientific, Waltham, 
MA, USA), and served as a template for insert 
amplification (Sequences 5’-3’: forward primer: 
CGAAGCTTCACCATGGGTGCTCCGGCGCTGC and 
reverse primer: CGTCTAGAGTCAGCGTAA 
GGCAGCC AGCTG) using High Fidelity DNA 
Polymerase (#M0530, New England Biolabs, Ipswich, 
MA, USA). The insert was subcloned into a pcDNA3.1 
vector (Thermo Fisher Scientific, Waltham, MA, USA) 
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using XbaI and HindIII-HF restriction enzymes (#R0145 
and #R3104, New England Biolabs, Ipswich, MA, USA). 
Ligation was performed using T4 DNA ligase (#M0202, 
New England Biolabs, Ipswich, MA, USA) at 16°C 
overnight. After heat shock transformation of chemical 
competent Escherichia coli DH5α, bacteria were plated 
on ampicillin-containing LB agar and grown at 37°C 
overnight. Next day colonies were checked and two of 
the positive clones were separately grown in liquid LB 
at 37°C overnight. For isolation of recombinant DNA 
PureLink HiPure Plasmid Midiprep Kit (#K2100-03, 
Thermo Fisher Scientific, Waltham, MA, USA) was 
used. Before transfection, the sequence of the construct 
was confirmed with bidirectional Sanger sequencing 
using the following primers (5’-3’) located on the vector: 
forward primer: AGAACCCACTGCTTACTGGC, 
reverse primer: GGCAAACAACAGATGGCTGG.
Caspase-3 apoptosis assay
Caspase-3 activity of cells was determined using a 
Caspase-3 Colorimetric Protease Assay Kit (#KHZ0021, 
Thermo Fisher Scientific, Waltham, MA, USA) according 
to the manufacturer’s instructions. Briefly, after 72 hours 
of treatment, cells were re-suspended in chilled cell 
lysis buffer and incubated on ice for 10 min. After 1 min 
centrifugation at 10000 x g, protein concentrations of the 
supernatants (cytosol extract) were measured using BCA 
Protein Assay Kit (#B6916, Sigma, St. Louis, MO, USA). 
Equal amounts of proteins were then incubated at 37°C 
with Reaction Buffer containing 10 mM DTT and 200 uM 
DEVD-pNA substrate for 2 hours. The optical density was 
measured at 405 nm with a Thermo Scientific Varioskan 
Flash plate reader (Thermo Fisher Scientific, Waltham, 
MA, USA).
Trypan blue exclusion assay
Cells were seeded in a 6-well plate 24 hours before 
treatment. After the indicated treatment cells were stained 
with Trypan blue (#15250, Thermo Fisher Scientific, 
Waltham, MA, USA), which can be taken up only by 
viable cells. Viable and dead cells were counted using a 
Burker’s chamber.
DNA fragmentation assay
DNA degradation is a key indicating factor of the 
presence of either apoptosis or necrosis. For detection 
of cell death by DNA fragmentation assay, cells were 
seeded in a 6-well plate 24 hours before treatment. After 
treatment DNA was isolated from cells using QIAamp 
DNA Mini Kit (#51304, Qiagen, Hilden, Germany) 
and analyzed on 1% agarose gel containing ethidium-
bromide.
Xenograft experiment
Inbred SCID mice were used for generating GH3 
and RC-4 B/C xenograft models. Experiments were 
carried out in accordance with the animal protection 
laws of the Ethic Committee of Semmelweis University. 
6-8-week-old male mice were subcutaneously injected 
with GH3 and RC-4 B/C cells mixed with Matrigel 
Matrix (#354262, Corning) in one flank. Tumor size was 
measured once a week using calipers, and tumor volume 
was calculated as width2 × length × 0.5. As RC-4 B/C 
xenograft has been never generated before, we performed 
xenograft injection with gradually increasing cell number 
(5x106, 10x106 and 20x106/injection). We used two mice in 
every experiment and repeated it three times. As a positive 
control we also injected additional mice with GH3 cells 
(10x106) as positive control.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 6 software (GraphPad Software Inc., La Jolla 
California USA). For examining the differences in cell 
viability, proliferation, cell-cycle distribution, mRNA and 
protein expression one-way ANOVA was used followed 
by Tukey’s multiple comparisons test. Investigating 
correlation between survivin expression and Ki67 index 
Spearman correlation was used. For comparison of 
staining scores between adenoma and normal tissues 
Welch's unequal variances t-test was used. Fisher’s exact 
test was applied to compare the prevalence of moderate 
and strong positivity between adenoma and normal 
samples. P-values < 0.05 were considered significant.
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